Department of Psychiatry, School of Medicine, University of Zambia (UNZA).
Research Article
World Journal of Advanced Research and Reviews, 2020, 07(02), 082-088
Article DOI: 10.30574/wjarr.2020.7.2.0283
Received on 28 July 2020; revised on 05 August 2020; accepted on 09 August 2020
Parkinson’s disease (PD) is a progressive neurological disorder characterized by a large number of motor and non-motor features that can impact on function to a variable degree. The syndrome of parkinsonism is recognized, which can become apparent with akinetic rigid disorders in other brain injuries and medication-induced parkinsonism. Genetic mutations or variants, neuroimaging abnormalities and other tests are potential biomarkers that may improve diagnosis and allow the identification of persons at risk. This literature review describes pathogenesis and clinical characteristics of PD with emphasis on modern treatment and possibilities of dopamine agonists, especially pramipexole. During pramipexole treatment of the patients with the early and late stages of PD, we can observe the reduction of expression of cognitive and affective (mood) disorders, the improvement of the quality of life and social functioning.
Parkinson’s disease; Neurodegenerative disease; Neuropsychiatry; Psychopharmacology; Pramipexole; Depression
Preview Article PDF
Anatolii Tsarkov and Petro Petlovanyi. Use of pramipexole in neuropsychiatry. World Journal of Advanced Research and Reviews, 2020, 7(2), 082-088. Article DOI: https://doi.org/10.30574/wjarr.2020.7.2.0283